Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...

Novavax has transferred commercialization of its COVID-19 vaccine in Europe to Sanofi. The company is shifting focus to ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

Are we ready to go? Are we live? Hello, everyone. Hi, I'm John Jacobs, CEO of Novavax, and I'm joined here today by Jim Kelly, our CFO; and Dr. Ruxandra Draghia, who heads up our R&D. I want to thank ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novavax (NASDAQ:NVAX) and its peers.

Good morning, and welcome to Novavax's Third Quarter 2025 Financial Results and Operational Highlights Conference Call. [Operator Instructions] Please note this event is being recorded, and I would ...

Novavax benefited from this deal, but moving forward, there is far too much uncertainty surrounding it. For one, demand for coronavirus vaccines might no longer be what it once was. That's on top of ...

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Novavax is a biotechnology company specializing in the ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M ...

GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025. ...